মাল্টা - ইংরেজি - Medicines Authority

jv healthcare limited navi buidlings, pantar road, lija, lja 2021, malta - vincristine sulfate - solution for injection - vincristine sulfate 1 mg/ml - antineoplastic agents

কানাডা - ইংরেজি - Health Canada

david bull laboratories (pty) ltd. - vincristine sulfate - liquid - 1mg - vincristine sulfate 1mg - antineoplastic agents

কানাডা - ইংরেজি - Health Canada

david bull laboratories (pty) ltd. - vincristine sulfate - powder for solution - 5mg - vincristine sulfate 5mg - antineoplastic agents

মাল্টা - ইংরেজি - Medicines Authority

central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - vincristine sulfate - solution for injection - vincristine sulfate 1 mg/ml - antineoplastic agents

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

vincristine sulfate -

আয়ার্লণ্ড - ইংরেজি - HPRA (Health Products Regulatory Authority)

hospira uk ltd - vincristine sulfate - solution for injection - 5 mg/5ml

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

talon therapeutics, inc. - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - vincristine sulfate 5 mg in 5 ml - marqibo® is indicated for the treatment of adult patients with philadelphia chromosome-negative (ph-) acute lymphoblastic leukemia (all) in second or greater relapse or whose disease has progressed following two or more anti-leukemia therapies. this indication is based on overall response rate. clinical benefit such as improvement in overall survival has not been verified. marqibo is contraindicated in patients with demyelinating conditions including charcot-marie-tooth syndrome. marqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of marqibo (vincristine sulfate liposome injection). marqibo is contraindicated for intrathecal administration. pregnancy category d [see warnings and precautions (5.9) ] based on its mechanism of action and findings from animal studies, marqibo can cause fetal harm when administered to pregnant women. if this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be

মার্কিন যুক্তরাষ্ট্র - ইংরেজি - NLM (National Library of Medicine)

teva parenteral medicines, inc. - vincristine sulfate (unii: t5iro3534a) (vincristine - unii:5j49q6b70f) - vincristine sulfate 1 mg in 1 ml - vincasar pfs is indicated in acute leukemia. vincasar pfs has also been shown to be useful in combination with other oncolytic agents in hodgkin’s disease, non-hodgkin’s malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and wilms’ tumor. patients with the demyelinating form of charcot-marie-tooth syndrome should not be given vincasar pfs. careful attention should be given to those conditions listed under warnings  and precautions .

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: benzyl alcohol; mannitol; water for injections - vincristine sulphate injection is used in the treatment of cancers of the blood (eg. leukaemia or lymphomas), breast, head and neck or lung. it may be used to treat multiple myeloma (a cancer of plasma cells) and it may also be used in the treatment of some cancers in children. it may be used in a blood disorder known as idiopathic thrombocytopenic purpura (itp) after other treatments have not been successful. vincristine sulphate injection may be given alone or in combination with other anti-cancer medicines.

অস্ট্রেলিয়া - ইংরেজি - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection - excipient ingredients: mannitol; water for injections; sulfuric acid; sodium hydroxide - vincristine sulfate is indicated in the treatment of acute leukemia. it has also been used in combination with other antineoplastic drugs in hodgkin's disease, soft-tissue sarcoma, bony-tissue sarcoma, sarcomas of specialized structures, breast cancer, small cell cancer of the lung, cancer of uterine cervix, malignant melanoma, colorectal cancer, non-hodgkin's lymphoma, and wilm's tumor.